BIB
ProShares Ultra Nasdaq Biotechnology [BIB] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BIB Stock Summary
Top BIB Correlated Resources
BIB
Top 10 Correlated ETFs
BIB
Top 10 Correlated Stocks
BIB
In the News
BIB Financial details
Company Rating
-
Market Cap
92.09M
Income
-
Revenue
-
Book val./share
-
Cash/share
-
Dividend
0.04
Dividend %
0.06%
Employees
-
Optionable
No
Shortable
Yes
Earnings
-
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-22.64%
SMA50
-26.79%
SMA100
-26.79%
Inst Own
-
Inst Trans
-
ROA
-
ROE
-
ROC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
40.1-62.45
52W High
-34.73%
52W Low
+1.16%
RSI
40
Rel Volume
0.12
Avg Volume
42.32K
Volume
5.08K
Perf Week
7.79%
Perf Month
-25.16%
Perf Quarter
-34.58%
Perf Half Y
-37.95%
-
-
-
-
Beta
1.31
-
-
Volatility
0.81%, 5.88%
Prev Close
-2.23%
Price
40.465
Change
-0.85%
BIB Financial Performance
BIB Frequently Asked Questions
What is ProShares Ultra Nasdaq Biotechnology stock symbol ?
ProShares Ultra Nasdaq Biotechnology is a US stock and trading under the symbol BIB
What is ProShares Ultra Nasdaq Biotechnology stock quote today ?
ProShares Ultra Nasdaq Biotechnology stock price is $40.465 today.
Is ProShares Ultra Nasdaq Biotechnology stock public?
Yes, ProShares Ultra Nasdaq Biotechnology is a publicly traded company.
Company Profile
- Volume Average 42.32K
- Market Capitalization 92.09M
- Headquarters US
- IPO Date 2010-04-09
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
